Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC - EurekAlert!
BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors - EurekAlert!
Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study - EurekAlert!
Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy - EurekAlert!
FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC - EurekAlert!
Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds - EurekAlert!
COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC - EurekAlert!
New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients - EurekAlert!
EGFR inhibitor-linked cytokine storms: study uncovers the trigger - EurekAlert!
Novel therapy shows promise for lung cancer patients with rare EGFR mutation
